The primary safety endpoint was the superiority of the arithmetic mean maximum decrease in haemoglobin concentration from enrolment to day 28 of follow-up in the primaquine treatment groups compared with placebo , with use of significance testing of pairwise comparisons with a cutoff of p = 0.05 .